MCMarie-Pierre Chenard

Marie-Pierre Chenard

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marie-Pierre Chenard has a total of 100 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Bone metastases from a 1p/19q codeleted and IDH1-mutant anaplastic oligodendroglioma: a case report

    by Mickaël Burgy, Marie-Pierre Chenard, Georges Noël, Khalil Bourahla, Roland Schott

    Oligodendroglioma is a rare type of primary brain tumor which, like other malignant gliomas, metastasizes very rarely even when in high-grade form. A 36-year-old white man diagnosed 29 months previously as having 1p/19q codeleted anaplastic oligodendroglioma presented bilateral cruralgia and lower limb motor deficits. A computed tomography scan showed multiple osteoblastic bone lesions. The presence of oligodendroglial cells was revealed by bone marrow biopsy and confirmed by immunohistochemical analyses. A positon emission tomography-computed tomography scan confirmed the exclusive involvement of bones. This case joins less than 20 other reported cases of oligodendroglioma bone marrow metastasis, and is one of only a handful of cases of diffuse bone metastases beyond the axial skeleton. To the best of our knowledge, the early relapse of 1p/19q codeleted anaplastic oligodendroglioma with this distribution of metastases has never been described in the literature.


  • Open Access

    Mutations in signal recognition particle SRP54 cause syndromic neutropenia with Shwachman-Diamond–like features

    by Raphael Carapito, Martina Konantz, Catherine Paillard, Zhichao Miao, Angélique Pichot, Magalie S. Leduc, Yaping Yang, Katie L. Bergstrom, Donald H. Mahoney, Deborah L. Shardy, et al.

    Shwachman-Diamond syndrome (SDS) (OMIM #260400) is a rare inherited bone marrow failure syndrome (IBMFS) that is primarily characterized by neutropenia and exocrine pancreatic insufficiency. Seventy-five to ninety percent of patients have compound heterozygous loss-of-function mutations in the Shwachman-Bodian-Diamond syndrome (sbds) gene. Using trio whole-exome sequencing (WES) in an sbds-negative SDS family and candidate gene sequencing in additional SBDS-negative SDS cases or molecularly undiagnosed IBMFS cases, we identified 3 independent patients, each of whom carried a de novo missense variant in srp54 (encoding signal recognition particle 54 kDa). These 3 patients shared congenital neutropenia linked with various other SDS phenotypes. 3D protein modeling revealed that the 3 variants affect highly conserved amino acids within the GTPase domain of the protein that are critical for GTP and receptor binding. Indeed, we observed that the GTPase activity of the mutated proteins was impaired. The level of SRP54 mRNA in the bone marrow was 3.6-fold lower in patients with SRP54-mutations than in healthy controls. Profound reductions in neutrophil counts and chemotaxis as well as a diminished exocrine pancreas size in a SRP54-knockdown zebrafish model faithfully recapitulated the human phenotype. In conclusion, autosomal dominant mutations in SRP54, a key member of the cotranslation protein-targeting pathway, lead to syndromic neutropenia with a Shwachman-Diamond–like phenotype.


  • Factors influencing HER2 positivity in breast cancer according to statistical modeling and data mining techniques based on a real-world national database: HER-France.

    by Marie-Pierre Chenard, Eric Anger, Marie-Helene Bizollon, Jerome Chetritt, Francesco Bruno Cutuli, Jean Kapfer, Magali Lacroix, Catherine Lefebvre, Eve Lefort, Gaetan mac Grogan, et al.

    E12086 Background: HER-France is a national database collecting information on HER2 status in invasive breast cancer supplied by 124 French pathology labs (FPL). It is conducted by the French Association for Quality Control in Histopathology (AFAQAP) since October 2011. Its goal is to follow the national HER2 rate and its change over time. An analysis of this database was carried in October 2015 on 105,717 records to search for factors associated with HER2 positivity. Methods: To identify these factors, multivariate regression models were applied, as well as supervised and unsupervised Data Mining techniques such as Bayesian Networks and Decision trees were used to represent dependencies between tumor characteristics and HER2 positivity. HER2 status was determined by immunohistochemistry and in situ hybridization using ASCO/CAP 2013 guidelines. To avoid bias due to adverse pre-analytic conditions, only results on Core-Biopsies (CB) are presented hereafter. Results: Out of 105,717 records, 45,785 (43.3%) CB were analyzed. 41,586 (90.8%) CB were evaluable for HER2 status and 4,976 (12.0%) were HER2+. Factors influencing HER2 positivity were No Special Type histologic subtype (OR=2.27, 95%CI [1.89-2.77]), high histologic grade (OR=4.71, 95%CI [3.86-5.76]), negative or low hormonal receptor status (OR=1.85, 95%CI [1.67-2.04]), and higher Ki67 index (OR=3.06, 95%CI [2.72-3.44]). Bayesian Network confirmed the importance of these parameters, providing thresholds linked to high HER2 positivity rates, as shown in table below. Conclusions: HER-France is a nationwide database showing 12.0% of HER2+ on breast cancer CB between 2011 and 2015. Histological subtype, grade and ER-PR status as reported in the German database study (Ruschoff et al.), but also Ki67 are factors influencing HER2 positivity. In the future, these results should be integrated to develop new HER-France functionalities in order to allow FPL to compare their actual HER2 rate to the expected HER2 rate based on these factors.

  • Checking HER2 rates in breast cancer: A 4 year-experience with a nationwide database containing 105,717 records—HER-France.

    by Marie-Pierre Chenard, Eric Anger, Marie-Helene Bizollon, Jerome Chetritt, Jean Kapfer, Magali Lacroix, Catherine Lefebvre, Eve Lefort, Elisabeth Luporsi-Gely, Gaetan mac Grogan, et al.

    E12089 Background: AFAQAP (French national quality control association in histopathology) has developed HER-France, a website tool collecting data concerning breast cancer characterization updated by pathologists. The aim of HER-France is to collect, analyze and provide consolidated data to monitor at a national and individual laboratory level the HER2 rate, and also other usual predictive and prognostic factors. It allows every participating lab to compare its own data with the national data (obtained by aggregation of data of all participating labs) to detect possible deviations from reference conditions and amend their practice if necessary. The use of HER-France is cost-free and available to all French Pathology Laboratories (FPL) on a voluntary basis since October 2011. Anonymity of the participants is protected. Roche supports AFAQAP to realize statistical analysis on HER-France database. Methods: Collected data include type of sample (core-biopsy [CB] vs lumpectomy/mastectomy), tumor type and grade, percentage of positive tumor cells for ER, PR and Ki67, mean staining intensity for ER and PR, HER2 score by immunohistochemistry (IHC) and amplification status by in situ hybridization (ISH). Results: Up to October 2015, 124 public and private FPL used HER-France and 105,717 data on specimens have been collected, among which 55,199 on CB. In order to avoid possible bias in the IHC/ISH results due to adverse pre-analytical conditions, focus was made on 45,785 untreated primitive CB of primary tumors and 2,382 metastases. The HER2 overexpression rate average since 2011 is 12.0% on primary tumors and 14.6% on metastases. Most labs that initially were outliers came gradually closer to this average. Regarding primary tumors, HER2 positivity rate was 13.5%, 4.0%, 5.0% and 0.6% for No Special Type (NST), lobular, mucinous and tubular carcinoma respectively. HER2 positivity rate for NST and lobular carcinoma was 2.8%, 11.6% and 26.6% for grade 1, 2 and 3 respectively. Conclusions: HER-France produces indicators to monitor quality of prognostic/predictive factors in breast cancer. It permits FPL to follow their own HER2 overexpression rate and compare their results to the mean national rate.

  • Evolution of HER2 testing practices in breast cancer in France from 2005 to 2015: Results of the PartenHER national survey.

    by Frederique Madeleine Penault-Llorca, Jerome Chetritt, Bruno Poulet, Marie-Pierre Chenard, Magali Lacroix-Triki, Laurent Arnould, Gaetan mac Grogan, Jean-Pierre Bellocq

    E12082 Background: For many years, French pathologists have been striving to standardize their practices and improve the quality of HER2 testing in breast cancer. The PartenHER survey aimed to assess how practices have evolved over the last decade. Methods: The PartenHER national survey is based on a questionnaire developed by a scientific committee and sent by postal mail in February 2015. Each French anatomo-cytopathology (ACP) labs received only one questionnaire. The formular was composed of 41 questions including typology of ACP labs, different technical conditions observed during pre-analytical, analytical, post-analytical steps, difficult-to-classify HER2 test results, quality controls, staff organization and training. Results: By 30 July 2015, 109 ACP labs (53% private, 47% public) regularly testing for HER2 and representing almost 620 pathologists (i.e. one third of the French pathologists) had completed the questionnaire. The study showed that in 2015, the immunohistochemistry (IHC) technique was performed by all labs, 42% of which were also performing the in situ hybridization (ISH) technique. The IHC technique was automated in 100 % of the labs, two thirds of them being automated for more than 10 years. ISH was automated in 83% of the structures and in place for more than 10 years in 20% of the cases and for five years in 56%. Several improvements in practices were also reported. Formalin is now the fixative used by 89% of labs. In 2015, 79% of the preformatted request forms were designed to collect the time of tissue removal (vs 12% in 2005), 87% were using a 3+ score reference tissue on each slide (vs 17% in 2005), 81% were tracking the HER2 overexpression rate mostly by using the HER-France national database, and 94% participated in proficiency testing, even though 42% of them had never been audited by an external authority. Conclusions: The PartenHER national survey showed that French pathologists, despite their diversity, have amended and standardized their practices regarding HER2 testing in breast cancer over the last 10 years. Further progress remains to be made, in particular to monitor the HER2 overexpression rate and resort to external audits.

  • Open Access

    HER2 gene and protein expression status of breast carcinoma can be reliably tested on a single slide

    by Marie-Pierre Chenard, Marie-Pierre Wissler, Noëlle Weingertner, Carole Mathelin, Jean-Pierre Bellocq

    Human epidermal growth factor receptor 2 (HER2) status in breast carcinomas serves as a predictor of benefit from anti-HER2 therapy. In providing clinicians with the information necessary to decide whether or not to treat with targeted therapy, it might be necessary to choose between methods assessing HER2 protein overexpression or gene amplification. A new diagnostic approach could be a combination of both tests on the same slide. If accurate and reproducible, this approach might optimize patient stratification for therapy. In this study, formalin-fixed paraffin-embedded tumor samples from 77 breast cancer patients were examined for HER2 by immunohistochemistry (IHC) and silver in situ hybridization (SISH) using HER2 IHC (clone 4B5), HER2/CEN17SISH, and combined IHC and SISH assay, called gene protein (GP). Cases were selected to ensure a sufficient number of borderline cases on the basis of IHC scores (0, 1+, 2+, 3+), obtained during diagnostic histopathological workup. The concordance between the HER2 IHC score obtained during diagnostic histopathological workup and GP was 93 %. Discordances had no influence on therapy decisions. The concordance between ISH results using dual ISH (DISH) and GP was 96 %. Of the 77 cases studied by GP, three cases with a ratio close to 2 would have been called amplified by DISH. The use of GP reduced the time for slide reading for a trained pathologist by up to 25 %, relative to sequential reading of IHC followed by SISH. For cases with an IHC score of 2+, the final result was obtained in 1 day, while the sequential technique would have required retesting by ISH on a second day. In conclusion, assessment of HER2 status by GP is an improvement for pathologists and facilitates clinical decision-making for breast cancer management.